iBio (IBIO) Other Non-Current Assets (2011 - 2026)
iBio (IBIO) posted quarterly Other Non-Current Assets of $200000.0 for Q1 2026, little changed year-over-year from $200000.0 in Q1 2025, and up 1900.0% quarter-over-quarter from $10000.0 in Q4 2025.
iBio (IBIO) Other Non-Current Assets (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Other Non-Current Assets for 12 consecutive years, with $200000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $200000.0 (changed 0.0% YoY), while the FY2025 annual figure was $26000.0, down 87.91% from the prior year.
- Other Non-Current Assets rose to $200000.0 in Q1 2026 per IBIO's latest filing, from $10000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $6.0 million in Q3 2022 and bottomed at $10000.0 in Q4 2025.
- Historically, Other Non-Current Assets has averaged $984882.4 across 5 years, with a median of $223000.0 in 2024.
- On a YoY basis, Other Non-Current Assets climbed as much as 3962.5% in 2022 and fell as far as 95.74% in 2022.
- iBio's Other Non-Current Assets stood at $253000.0 in 2022, then jumped by 413.83% to $1.3 million in 2023, then slumped by 82.85% to $223000.0 in 2024, then plunged by 95.52% to $10000.0 in 2025, then jumped by 1900.0% to $200000.0 in 2026.
- Business Quant data shows IBIO's Other Non-Current Assets at $200000.0 in Q1 2026, $10000.0 in Q4 2025, and $228000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 282,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 223,000.00 |
| Sep 30, 2024 | 223,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Mar 31, 2024 | 215,000.00 |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 3.30 Mn |
| Dec 31, 2022 | 253,000.00 |
| Sep 30, 2022 | 6.00 Mn |
| Jun 30, 2022 | 29,000.00 |
| Mar 31, 2022 | 975,000.00 |
| Dec 31, 2021 | 5.94 Mn |
| Sep 30, 2021 | 1.30 Mn |
| Mar 31, 2021 | 24,000.00 |